Hypothesis: Transient expression of the OSK (Oct4, Sox2, Klf4) reprogramming factors specifically during NREM sleep enhances the brain’s waste clearance capacity by demethylating and reactivating key glymphatic and autophagy genes. This process depends on TET1/TET2-mediated oxidation of 5‑methylcytosine at promoter CpG sites of AQP4, ATG7 and BECN1, leading to increased chromatin accessibility, transcriptional upregulation, and functional restoration of astrocytic water channel polarization and autophagosome formation. Consequently, mistimed or absent OSK activity during sleep fails to reset these loci, resulting in age‑related decline of CSF‑interstitial fluid exchange and protein aggregate degradation, which accelerates neurodegeneration.

Mechanistic rationale:

• NREM sleep is characterized by low norepinephrine, expanded extracellular space (~60%), and peak glymphatic inflow, creating a window of heightened chromatin plasticity due to reduced histone deacetylase activity and increased NAD+‑dependent sirtuin signaling.
• OSK induces TET1/TET2 expression in multiple tissues; TET enzymes preferentially target CpG islands in promoters of stress‑response and homeostasis genes during periods of low metabolic flux.
• AQP4 perivascular polarization, ATG7‑dependent autophagy initiation, and BECN1‑mediated phagophore nucleation are epigenetically silenced in aging astrocytes and microglia, contributing to reduced CSF influx and impaired lysosomal degradation.
• Demethylation of these promoters during NREM sleep would restore youthful expression levels, thereby boosting convective CSF flow and autophagic clearance of Aβ, tau, and α‑synuclein.

Testable predictions:

1. In young adult mice, inducible OSK activation restricted to NREM sleep (using a sleep‑state‑dependent Cre driver) will increase AQP4 membrane polarity (measured by immunofluorescence polarity index) and autophagic flux (LC3‑II turnover) compared to OSK activation during wakefulness or constant expression.
2. Bisulfite sequencing of isolated astrocytes will show significant hypomethylation at specific CpG sites within the AQP4, ATG7 and BECN1 promoters only after NREM‑locked OSK pulses.
3. Pharmacological inhibition of TET1/2 (e.g., with Bobcat339) during NREM‑OSK treatment will abolish the epigenetic and functional improvements, confirming TET dependence.
4. Aged mice receiving weekly NREM‑locked OSK cycles for three months will exhibit reduced CSF tracer influx delay (MRI‑based glymphatic imaging) and lower insoluble tau accumulation than aged controls receiving OSK at random times or vehicle.
5. Disruption of NREM sleep (e.g., frequent acoustic arousal) will prevent OSK‑driven demethylation and clearance benefits, linking sleep architecture to epigenetic resetting efficacy.

Falsifiability: If OSK expression during NREM sleep fails to alter promoter methylation, does not enhance AQP4 polarization or autophagic activity, or does not improve glymphatic clearance despite confirmed transgene expression, the hypothesis is refuted. Conversely, observing the predicted epigenetic and physiological changes only when OSK is coupled to the NREM phase would support the model that sleep provides a permissive epigenetic state for targeted rejuvenation of the brain’s disposal systems.